After making a splash in the U.K. earlier this year, GSK is laying out plans for its biggest U.S. manufacturing investment ...

The CDC seems to be taking an “if it ain’t broke” approach to its annual flu vaccine push. | The CDC seems to be taking an ...

“These promising data add to the evidence supporting GSK’s RSV vaccine and could help expand protection to more adults at ...

The recent trial flop for Ztalmy, this time in tuberous sclerosis complex (TSC)-associated seizures, leaves the company in a ...

Many people don’t know they’re eligible. | Moderna has identified a fundamental barrier to vaccination: many people don’t ...

Rentschler acquired the Milford facility—its entry into the U.S. market—from Shire in 2019. The CDMO also operates a third ...

The war is on between compounding pharmacies making knockoff versions of popular weight loss drugs and pharma giants Novo ...

With an expanded recommendation from the Center for Disease Control and Prevention (CDC)’s Advisory Committee on Immunization ...

By squeezing Regeneron’s Eylea, eye disease drug Vabysmo has become one of the biggest growth drivers for Roche. | Despite ...

Genentech, the biotech unit of Swiss major Roche, has been marketing lung cancer drugs for nearly two decades, starting with ...

While Regeneron may have lost its latest bid to block the launch of Amgen’s Eylea biosimilar Pavblu, the New York-based ...

The groups behind the letter alleged that Novo Nordisk’s plant purchases could hinder not only the Danish drugmaker’s chief ...